CIRB #H-42687\/ CTSU #A011801 (CompassHER2-RD):<\/strong><\/a> CompassHER2 Residual Disease – A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib\u00a0<\/span><\/p>\n CIRB #H-45164\/ NRG BR007 DEBRA:<\/strong><\/strong><\/a> A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (pending IRB)<\/b><\/p>\n Central IRB #pend\/ AstraZeneca #AZD9833-D8536C0001 (SERENA-8):<\/strong><\/strong><\/a> A Randomised, Multicentre, Open-Label, Phase III study of Camizestrant + Capivasertib Versus Physician’s Choice of Endocrine-Based Therapy in Patients with Estrogen Receptor-Positive, HER2-Negative Inoperable Locally Advanced or Metastatic Breast Cancer Whose Disease has Progressed on Treatment with an Aromatase Inhibitor + CDK4\/6 inhibitor (pending sponsor)<\/b><\/p>\n CIRB #H-44585\/ SWOG #S2212 (SCARLET):<\/strong><\/strong><\/a> Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study<\/p>\n CIRB #H-44586\/ CTSU #A012103 (OptimICE-pCR):<\/strong><\/strong><\/a> De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy<\/p>\n CIRB #H-43958\/ ETCTN 10525:<\/strong><\/strong><\/a> A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer (pending)<\/b><\/p>\n CIRB #H-42956\/ ETCTN #10449:<\/strong><\/strong><\/a> A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer (temporary closure)<\/b><\/p>\nHormone Receptor-Positive & HER2-Negative<\/h4>\n
Triple Negative<\/h4>\n
Imaging<\/h4>\n